Acalabrutinib

CALQUENCE, manufactured by Lucius Pharmaceuticals, is a highly effective BTK inhibitor that demonstrates excellent efficacy and safety, providing patients with a reliable clinical treatment option.

Overview of Key Information About Acalabrutinib

Active Ingredient

Its main active ingredient is acalabrutinib, which belongs to the class ofBruton's Tyrosine Kinase (BTK) inhibitors.

Target Population

It is indicated for eligible adult patients with mantle cell lymphoma (MCL),chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).

Dosage and Administration

The recommended dosage is 100 mg taken orally approximately every 12 hours.
It can be administered with or without food.Reference Article: Dosage and Administration of Acalabrutinib

Use in Specific Populations

It is contraindicated in pregnant women.

Lactating women should discontinue breastfeeding during treatment.

Patients with severe hepatic impairment should avoid using thismedication.

Drug Overdose

Specific information on drug overdose has not been clearly documented. If an overdose occurs, medical assistance should be sought immediately.

Storage

The medication should be stored at 20°C–25°C, and protected from high temperatures and moisture.

Pharmacokinetics

In terms of pharmacokinetics, acalabrutinib is rapidly absorbed after oral administration. It is mainly metabolized by CYP3A, with a relatively short half-life.

FDA，2025.01